Danaher (NYSE:DHR) Upgraded at UBS Group

UBS Group upgraded shares of Danaher (NYSE:DHR) to a strong-buy rating in a report released on Wednesday morning,Zacks reports.

Other research analysts have also recently issued reports about the stock. Royal Bank Of Canada raised their target price on shares of Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a report on Wednesday, July 22nd. Wells Fargo & Company dropped their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Finally, Wolfe Research cut shares of Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Stock Down 0.1%

DHR stock opened at $200.30 on Wednesday. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The firm has a market cap of $140.81 billion, a PE ratio of 35.58, a P/E/G ratio of 2.50 and a beta of 0.78. The firm has a 50 day simple moving average of $202.65 and a 200 day simple moving average of $192.08. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.77 earnings per share. Equities research analysts forecast that Danaher will post 8.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DHR. Main Street Group LTD bought a new stake in Danaher during the 1st quarter valued at approximately $25,000. N.E.W. Advisory Services LLC bought a new stake in shares of Danaher in the second quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter worth $25,000. WFA of San Diego LLC bought a new position in Danaher during the second quarter worth $26,000. Finally, Hilton Head Capital Partners LLC bought a new position in Danaher during the fourth quarter worth $27,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.